In attempt to assess treatment patterns in advanced gastric cancer across racial and ethnic groups throughout the U.S., ...

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...

Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) has been made available within NHS Scotland for the first line treatment of adult patients with mismatch repair deficient (dMMR) or ...

Immunotherapy is offering new hope for cancers that once had grim prognoses by harnessing the body's own immune system to ...

In a Jan. 13th installation of the Stanford Cancer Institute’s “Breakthroughs in Cancer” lecture series, Lawrence Fong ...

Combination therapy of botensilimab (BOT) plus balstilimab (BAL) was approved Monday as an updated national treatment protocol for patients with certain ovarian cancers and soft tissue sarcomas (STS) ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

Colorectal cancer, the abnormal growth of cancerous cells in the large intestine or the rectum, is one of the most common ...

Studies published in Nature Cancer reveal how bacterial presence in head and neck cancers affects treatment response, ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...